nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—EGFR—bone cancer	0.599	1	CbGaD
Afatinib—ABCG2—Carboplatin—bone cancer	0.0521	0.271	CbGbCtD
Afatinib—ABCG2—Cisplatin—bone cancer	0.0445	0.231	CbGbCtD
Afatinib—ABCG2—Doxorubicin—bone cancer	0.0298	0.155	CbGbCtD
Afatinib—ABCG2—Methotrexate—bone cancer	0.0289	0.15	CbGbCtD
Afatinib—ABCB1—Cisplatin—bone cancer	0.016	0.0833	CbGbCtD
Afatinib—ABCB1—Doxorubicin—bone cancer	0.0108	0.0559	CbGbCtD
Afatinib—ABCB1—Methotrexate—bone cancer	0.0104	0.0541	CbGbCtD
Afatinib—Ventricular dysfunction—Epirubicin—bone cancer	0.00363	0.0558	CcSEcCtD
Afatinib—Pulmonary toxicity—Cisplatin—bone cancer	0.00359	0.0551	CcSEcCtD
Afatinib—Ventricular dysfunction—Doxorubicin—bone cancer	0.00336	0.0516	CcSEcCtD
Afatinib—Gefitinib—CHEK2—bone cancer	0.00289	0.472	CrCbGaD
Afatinib—Paronychia—Methotrexate—bone cancer	0.00258	0.0396	CcSEcCtD
Afatinib—Pulmonary toxicity—Methotrexate—bone cancer	0.00197	0.0303	CcSEcCtD
Afatinib—Vandetanib—EGFR—bone cancer	0.00122	0.198	CrCbGaD
Afatinib—Gefitinib—EGFR—bone cancer	0.00116	0.188	CrCbGaD
Afatinib—Rhinorrhoea—Cisplatin—bone cancer	0.00101	0.0155	CcSEcCtD
Afatinib—Infection—Carboplatin—bone cancer	0.000984	0.0151	CcSEcCtD
Afatinib—Aphthous stomatitis—Epirubicin—bone cancer	0.000892	0.0137	CcSEcCtD
Afatinib—Aphthous stomatitis—Doxorubicin—bone cancer	0.000825	0.0127	CcSEcCtD
Afatinib—Mucosal inflammation—Methotrexate—bone cancer	0.000807	0.0124	CcSEcCtD
Afatinib—Body temperature increased—Carboplatin—bone cancer	0.000783	0.012	CcSEcCtD
Afatinib—Mucosal inflammation—Epirubicin—bone cancer	0.000755	0.0116	CcSEcCtD
Afatinib—Mucosal inflammation—Doxorubicin—bone cancer	0.000699	0.0107	CcSEcCtD
Afatinib—Keratitis—Epirubicin—bone cancer	0.000645	0.00991	CcSEcCtD
Afatinib—Interstitial lung disease—Methotrexate—bone cancer	0.000631	0.0097	CcSEcCtD
Afatinib—Keratitis—Doxorubicin—bone cancer	0.000597	0.00917	CcSEcCtD
Afatinib—Dehydration—Cisplatin—bone cancer	0.00055	0.00845	CcSEcCtD
Afatinib—Hypokalaemia—Cisplatin—bone cancer	0.000538	0.00827	CcSEcCtD
Afatinib—DYRK1A—Doxorubicin—Epirubicin—bone cancer	0.000537	0.0946	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Epirubicin—bone cancer	0.000537	0.0946	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Epirubicin—bone cancer	0.000537	0.0946	CbGdCrCtD
Afatinib—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.000532	0.00818	CcSEcCtD
Afatinib—Nasopharyngitis—Cisplatin—bone cancer	0.000529	0.00812	CcSEcCtD
Afatinib—DYRK1A—Daunorubicin—Doxorubicin—bone cancer	0.000497	0.0875	CbGdCrCtD
Afatinib—DYRK1A—Epirubicin—Doxorubicin—bone cancer	0.000497	0.0875	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Doxorubicin—bone cancer	0.000497	0.0875	CbGdCrCtD
Afatinib—Renal failure—Cisplatin—bone cancer	0.000448	0.00688	CcSEcCtD
Afatinib—Vandetanib—CYP3A4—bone cancer	0.000444	0.0724	CrCbGaD
Afatinib—Stomatitis—Cisplatin—bone cancer	0.000444	0.00683	CcSEcCtD
Afatinib—Conjunctivitis—Cisplatin—bone cancer	0.000443	0.00681	CcSEcCtD
Afatinib—Cystitis noninfective—Methotrexate—bone cancer	0.000436	0.00671	CcSEcCtD
Afatinib—Cystitis—Methotrexate—bone cancer	0.000431	0.00663	CcSEcCtD
Afatinib—Hepatobiliary disease—Cisplatin—bone cancer	0.000431	0.00662	CcSEcCtD
Afatinib—Gefitinib—CYP3A4—bone cancer	0.000422	0.0688	CrCbGaD
Afatinib—ERBB2—Doxorubicin—Epirubicin—bone cancer	0.000413	0.0728	CbGdCrCtD
Afatinib—Cystitis noninfective—Epirubicin—bone cancer	0.000408	0.00628	CcSEcCtD
Afatinib—Bladder pain—Methotrexate—bone cancer	0.000404	0.00621	CcSEcCtD
Afatinib—Mouth ulceration—Methotrexate—bone cancer	0.000404	0.00621	CcSEcCtD
Afatinib—Urinary tract disorder—Cisplatin—bone cancer	0.000404	0.00621	CcSEcCtD
Afatinib—Cystitis—Epirubicin—bone cancer	0.000404	0.00621	CcSEcCtD
Afatinib—Connective tissue disorder—Cisplatin—bone cancer	0.000402	0.00618	CcSEcCtD
Afatinib—Urethral disorder—Cisplatin—bone cancer	0.000401	0.00616	CcSEcCtD
Afatinib—Sepsis—Methotrexate—bone cancer	0.000388	0.00596	CcSEcCtD
Afatinib—Dry eye—Epirubicin—bone cancer	0.000386	0.00594	CcSEcCtD
Afatinib—ERBB2—Epirubicin—Doxorubicin—bone cancer	0.000382	0.0673	CbGdCrCtD
Afatinib—Eye disorder—Cisplatin—bone cancer	0.000382	0.00587	CcSEcCtD
Afatinib—Bladder pain—Epirubicin—bone cancer	0.000378	0.00581	CcSEcCtD
Afatinib—Mouth ulceration—Epirubicin—bone cancer	0.000378	0.00581	CcSEcCtD
Afatinib—Cystitis noninfective—Doxorubicin—bone cancer	0.000378	0.00581	CcSEcCtD
Afatinib—Cystitis—Doxorubicin—bone cancer	0.000374	0.00574	CcSEcCtD
Afatinib—Mediastinal disorder—Cisplatin—bone cancer	0.000369	0.00566	CcSEcCtD
Afatinib—Sepsis—Epirubicin—bone cancer	0.000363	0.00558	CcSEcCtD
Afatinib—Alopecia—Cisplatin—bone cancer	0.000361	0.00555	CcSEcCtD
Afatinib—Dry eye—Doxorubicin—bone cancer	0.000357	0.00549	CcSEcCtD
Afatinib—Malnutrition—Cisplatin—bone cancer	0.000356	0.00547	CcSEcCtD
Afatinib—Mouth ulceration—Doxorubicin—bone cancer	0.00035	0.00538	CcSEcCtD
Afatinib—Bladder pain—Doxorubicin—bone cancer	0.00035	0.00538	CcSEcCtD
Afatinib—Muscle spasms—Cisplatin—bone cancer	0.000342	0.00526	CcSEcCtD
Afatinib—Sepsis—Doxorubicin—bone cancer	0.000336	0.00516	CcSEcCtD
Afatinib—Renal impairment—Epirubicin—bone cancer	0.000319	0.0049	CcSEcCtD
Afatinib—ABL1—Doxorubicin—Epirubicin—bone cancer	0.000309	0.0543	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Epirubicin—bone cancer	0.000309	0.0543	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Epirubicin—bone cancer	0.000309	0.0543	CbGdCrCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000301	0.00463	CcSEcCtD
Afatinib—Renal impairment—Doxorubicin—bone cancer	0.000295	0.00454	CcSEcCtD
Afatinib—Infection—Cisplatin—bone cancer	0.000289	0.00444	CcSEcCtD
Afatinib—ABL1—Epirubicin—Doxorubicin—bone cancer	0.000285	0.0503	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Doxorubicin—bone cancer	0.000285	0.0503	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Doxorubicin—bone cancer	0.000285	0.0503	CbGdCrCtD
Afatinib—Nervous system disorder—Cisplatin—bone cancer	0.000285	0.00438	CcSEcCtD
Afatinib—Dehydration—Epirubicin—bone cancer	0.000282	0.00434	CcSEcCtD
Afatinib—Skin disorder—Cisplatin—bone cancer	0.000282	0.00434	CcSEcCtD
Afatinib—Dry skin—Epirubicin—bone cancer	0.000278	0.00428	CcSEcCtD
Afatinib—Hypokalaemia—Epirubicin—bone cancer	0.000276	0.00425	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000273	0.0042	CcSEcCtD
Afatinib—Nasopharyngitis—Epirubicin—bone cancer	0.000271	0.00417	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000268	0.00412	CcSEcCtD
Afatinib—Dehydration—Doxorubicin—bone cancer	0.000261	0.00402	CcSEcCtD
Afatinib—Upper respiratory tract infection—Methotrexate—bone cancer	0.000261	0.00401	CcSEcCtD
Afatinib—Dyspnoea—Cisplatin—bone cancer	0.000259	0.00398	CcSEcCtD
Afatinib—Dry skin—Doxorubicin—bone cancer	0.000257	0.00396	CcSEcCtD
Afatinib—Hypokalaemia—Doxorubicin—bone cancer	0.000256	0.00393	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000253	0.00389	CcSEcCtD
Afatinib—Decreased appetite—Cisplatin—bone cancer	0.000253	0.00388	CcSEcCtD
Afatinib—Pneumonia—Methotrexate—bone cancer	0.000251	0.00386	CcSEcCtD
Afatinib—Nasopharyngitis—Doxorubicin—bone cancer	0.000251	0.00386	CcSEcCtD
Afatinib—Gastrointestinal disorder—Cisplatin—bone cancer	0.000251	0.00386	CcSEcCtD
Afatinib—Infestation—Methotrexate—bone cancer	0.00025	0.00384	CcSEcCtD
Afatinib—Infestation NOS—Methotrexate—bone cancer	0.00025	0.00384	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000248	0.00381	CcSEcCtD
Afatinib—Renal failure—Methotrexate—bone cancer	0.000246	0.00378	CcSEcCtD
Afatinib—Upper respiratory tract infection—Epirubicin—bone cancer	0.000244	0.00375	CcSEcCtD
Afatinib—Stomatitis—Methotrexate—bone cancer	0.000244	0.00375	CcSEcCtD
Afatinib—Conjunctivitis—Methotrexate—bone cancer	0.000243	0.00373	CcSEcCtD
Afatinib—Weight decreased—Epirubicin—bone cancer	0.000237	0.00365	CcSEcCtD
Afatinib—Hepatobiliary disease—Methotrexate—bone cancer	0.000236	0.00363	CcSEcCtD
Afatinib—Epistaxis—Methotrexate—bone cancer	0.000236	0.00362	CcSEcCtD
Afatinib—Pneumonia—Epirubicin—bone cancer	0.000235	0.00362	CcSEcCtD
Afatinib—Infestation NOS—Epirubicin—bone cancer	0.000234	0.0036	CcSEcCtD
Afatinib—Infestation—Epirubicin—bone cancer	0.000234	0.0036	CcSEcCtD
Afatinib—Renal failure—Epirubicin—bone cancer	0.00023	0.00353	CcSEcCtD
Afatinib—Body temperature increased—Cisplatin—bone cancer	0.00023	0.00353	CcSEcCtD
Afatinib—Stomatitis—Epirubicin—bone cancer	0.000228	0.0035	CcSEcCtD
Afatinib—Urinary tract infection—Epirubicin—bone cancer	0.000227	0.0035	CcSEcCtD
Afatinib—Conjunctivitis—Epirubicin—bone cancer	0.000227	0.0035	CcSEcCtD
Afatinib—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000226	0.00347	CcSEcCtD
Afatinib—Urinary tract disorder—Methotrexate—bone cancer	0.000222	0.00341	CcSEcCtD
Afatinib—Hepatobiliary disease—Epirubicin—bone cancer	0.000221	0.0034	CcSEcCtD
Afatinib—Epistaxis—Epirubicin—bone cancer	0.000221	0.00339	CcSEcCtD
Afatinib—Urethral disorder—Methotrexate—bone cancer	0.00022	0.00338	CcSEcCtD
Afatinib—Weight decreased—Doxorubicin—bone cancer	0.00022	0.00338	CcSEcCtD
Afatinib—Pneumonia—Doxorubicin—bone cancer	0.000218	0.00335	CcSEcCtD
Afatinib—Infestation NOS—Doxorubicin—bone cancer	0.000216	0.00333	CcSEcCtD
Afatinib—Infestation—Doxorubicin—bone cancer	0.000216	0.00333	CcSEcCtD
Afatinib—Renal failure—Doxorubicin—bone cancer	0.000213	0.00327	CcSEcCtD
Afatinib—Stomatitis—Doxorubicin—bone cancer	0.000211	0.00324	CcSEcCtD
Afatinib—Urinary tract infection—Doxorubicin—bone cancer	0.00021	0.00323	CcSEcCtD
Afatinib—Conjunctivitis—Doxorubicin—bone cancer	0.00021	0.00323	CcSEcCtD
Afatinib—Eye disorder—Methotrexate—bone cancer	0.00021	0.00322	CcSEcCtD
Afatinib—Asthenia—Cisplatin—bone cancer	0.000208	0.0032	CcSEcCtD
Afatinib—Urinary tract disorder—Epirubicin—bone cancer	0.000207	0.00319	CcSEcCtD
Afatinib—Connective tissue disorder—Epirubicin—bone cancer	0.000206	0.00317	CcSEcCtD
Afatinib—Urethral disorder—Epirubicin—bone cancer	0.000206	0.00316	CcSEcCtD
Afatinib—Hepatobiliary disease—Doxorubicin—bone cancer	0.000205	0.00315	CcSEcCtD
Afatinib—Epistaxis—Doxorubicin—bone cancer	0.000204	0.00314	CcSEcCtD
Afatinib—Mediastinal disorder—Methotrexate—bone cancer	0.000202	0.00311	CcSEcCtD
Afatinib—Diarrhoea—Cisplatin—bone cancer	0.000199	0.00306	CcSEcCtD
Afatinib—Alopecia—Methotrexate—bone cancer	0.000198	0.00305	CcSEcCtD
Afatinib—Mental disorder—Methotrexate—bone cancer	0.000197	0.00302	CcSEcCtD
Afatinib—Eye disorder—Epirubicin—bone cancer	0.000196	0.00302	CcSEcCtD
Afatinib—Malnutrition—Methotrexate—bone cancer	0.000195	0.003	CcSEcCtD
Afatinib—Urinary tract disorder—Doxorubicin—bone cancer	0.000192	0.00295	CcSEcCtD
Afatinib—Dysgeusia—Methotrexate—bone cancer	0.000191	0.00294	CcSEcCtD
Afatinib—Connective tissue disorder—Doxorubicin—bone cancer	0.000191	0.00294	CcSEcCtD
Afatinib—Urethral disorder—Doxorubicin—bone cancer	0.00019	0.00293	CcSEcCtD
Afatinib—Mediastinal disorder—Epirubicin—bone cancer	0.000189	0.00291	CcSEcCtD
Afatinib—Back pain—Methotrexate—bone cancer	0.000189	0.0029	CcSEcCtD
Afatinib—Alopecia—Epirubicin—bone cancer	0.000186	0.00285	CcSEcCtD
Afatinib—Vomiting—Cisplatin—bone cancer	0.000185	0.00284	CcSEcCtD
Afatinib—Mental disorder—Epirubicin—bone cancer	0.000184	0.00283	CcSEcCtD
Afatinib—Rash—Cisplatin—bone cancer	0.000183	0.00282	CcSEcCtD
Afatinib—Dermatitis—Cisplatin—bone cancer	0.000183	0.00281	CcSEcCtD
Afatinib—Malnutrition—Epirubicin—bone cancer	0.000183	0.00281	CcSEcCtD
Afatinib—Eye disorder—Doxorubicin—bone cancer	0.000182	0.00279	CcSEcCtD
Afatinib—Dysgeusia—Epirubicin—bone cancer	0.000179	0.00275	CcSEcCtD
Afatinib—Back pain—Epirubicin—bone cancer	0.000177	0.00272	CcSEcCtD
Afatinib—Muscle spasms—Epirubicin—bone cancer	0.000176	0.0027	CcSEcCtD
Afatinib—Mediastinal disorder—Doxorubicin—bone cancer	0.000175	0.00269	CcSEcCtD
Afatinib—Nausea—Cisplatin—bone cancer	0.000173	0.00265	CcSEcCtD
Afatinib—Alopecia—Doxorubicin—bone cancer	0.000172	0.00264	CcSEcCtD
Afatinib—Cough—Methotrexate—bone cancer	0.00017	0.00262	CcSEcCtD
Afatinib—Mental disorder—Doxorubicin—bone cancer	0.00017	0.00262	CcSEcCtD
Afatinib—Malnutrition—Doxorubicin—bone cancer	0.000169	0.0026	CcSEcCtD
Afatinib—Dysgeusia—Doxorubicin—bone cancer	0.000166	0.00255	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000165	0.00254	CcSEcCtD
Afatinib—Back pain—Doxorubicin—bone cancer	0.000164	0.00251	CcSEcCtD
Afatinib—Muscle spasms—Doxorubicin—bone cancer	0.000163	0.0025	CcSEcCtD
Afatinib—Cough—Epirubicin—bone cancer	0.00016	0.00245	CcSEcCtD
Afatinib—Infection—Methotrexate—bone cancer	0.000158	0.00243	CcSEcCtD
Afatinib—Nervous system disorder—Methotrexate—bone cancer	0.000156	0.0024	CcSEcCtD
Afatinib—Skin disorder—Methotrexate—bone cancer	0.000155	0.00238	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000155	0.00238	CcSEcCtD
Afatinib—Infection—Epirubicin—bone cancer	0.000148	0.00228	CcSEcCtD
Afatinib—Cough—Doxorubicin—bone cancer	0.000148	0.00227	CcSEcCtD
Afatinib—Nervous system disorder—Epirubicin—bone cancer	0.000146	0.00225	CcSEcCtD
Afatinib—Skin disorder—Epirubicin—bone cancer	0.000145	0.00223	CcSEcCtD
Afatinib—Insomnia—Methotrexate—bone cancer	0.000144	0.00222	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000143	0.0022	CcSEcCtD
Afatinib—Dyspnoea—Methotrexate—bone cancer	0.000142	0.00218	CcSEcCtD
Afatinib—Dyspepsia—Methotrexate—bone cancer	0.00014	0.00216	CcSEcCtD
Afatinib—Decreased appetite—Methotrexate—bone cancer	0.000139	0.00213	CcSEcCtD
Afatinib—Gastrointestinal disorder—Methotrexate—bone cancer	0.000138	0.00212	CcSEcCtD
Afatinib—Fatigue—Methotrexate—bone cancer	0.000137	0.00211	CcSEcCtD
Afatinib—Infection—Doxorubicin—bone cancer	0.000137	0.00211	CcSEcCtD
Afatinib—Nervous system disorder—Doxorubicin—bone cancer	0.000135	0.00208	CcSEcCtD
Afatinib—Insomnia—Epirubicin—bone cancer	0.000135	0.00207	CcSEcCtD
Afatinib—Skin disorder—Doxorubicin—bone cancer	0.000134	0.00206	CcSEcCtD
Afatinib—Dyspnoea—Epirubicin—bone cancer	0.000133	0.00204	CcSEcCtD
Afatinib—Dyspepsia—Epirubicin—bone cancer	0.000131	0.00202	CcSEcCtD
Afatinib—Decreased appetite—Epirubicin—bone cancer	0.00013	0.00199	CcSEcCtD
Afatinib—Gastrointestinal disorder—Epirubicin—bone cancer	0.000129	0.00198	CcSEcCtD
Afatinib—Fatigue—Epirubicin—bone cancer	0.000129	0.00198	CcSEcCtD
Afatinib—Constipation—Epirubicin—bone cancer	0.000128	0.00196	CcSEcCtD
Afatinib—Body temperature increased—Methotrexate—bone cancer	0.000126	0.00194	CcSEcCtD
Afatinib—Insomnia—Doxorubicin—bone cancer	0.000125	0.00192	CcSEcCtD
Afatinib—Dyspnoea—Doxorubicin—bone cancer	0.000123	0.00189	CcSEcCtD
Afatinib—Dyspepsia—Doxorubicin—bone cancer	0.000122	0.00187	CcSEcCtD
Afatinib—Decreased appetite—Doxorubicin—bone cancer	0.00012	0.00184	CcSEcCtD
Afatinib—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000119	0.00183	CcSEcCtD
Afatinib—Fatigue—Doxorubicin—bone cancer	0.000119	0.00183	CcSEcCtD
Afatinib—Constipation—Doxorubicin—bone cancer	0.000118	0.00181	CcSEcCtD
Afatinib—Body temperature increased—Epirubicin—bone cancer	0.000118	0.00181	CcSEcCtD
Afatinib—Asthenia—Methotrexate—bone cancer	0.000114	0.00176	CcSEcCtD
Afatinib—Pruritus—Methotrexate—bone cancer	0.000113	0.00173	CcSEcCtD
Afatinib—Body temperature increased—Doxorubicin—bone cancer	0.000109	0.00168	CcSEcCtD
Afatinib—Diarrhoea—Methotrexate—bone cancer	0.000109	0.00168	CcSEcCtD
Afatinib—Asthenia—Epirubicin—bone cancer	0.000107	0.00165	CcSEcCtD
Afatinib—Pruritus—Epirubicin—bone cancer	0.000106	0.00162	CcSEcCtD
Afatinib—Dizziness—Methotrexate—bone cancer	0.000105	0.00162	CcSEcCtD
Afatinib—Diarrhoea—Epirubicin—bone cancer	0.000102	0.00157	CcSEcCtD
Afatinib—Vomiting—Methotrexate—bone cancer	0.000101	0.00156	CcSEcCtD
Afatinib—Rash—Methotrexate—bone cancer	0.000101	0.00155	CcSEcCtD
Afatinib—Dermatitis—Methotrexate—bone cancer	0.0001	0.00154	CcSEcCtD
Afatinib—Headache—Methotrexate—bone cancer	9.99e-05	0.00154	CcSEcCtD
Afatinib—Asthenia—Doxorubicin—bone cancer	9.9e-05	0.00152	CcSEcCtD
Afatinib—Dizziness—Epirubicin—bone cancer	9.87e-05	0.00152	CcSEcCtD
Afatinib—Pruritus—Doxorubicin—bone cancer	9.77e-05	0.0015	CcSEcCtD
Afatinib—Vomiting—Epirubicin—bone cancer	9.49e-05	0.00146	CcSEcCtD
Afatinib—Nausea—Methotrexate—bone cancer	9.47e-05	0.00146	CcSEcCtD
Afatinib—Diarrhoea—Doxorubicin—bone cancer	9.44e-05	0.00145	CcSEcCtD
Afatinib—Rash—Epirubicin—bone cancer	9.41e-05	0.00145	CcSEcCtD
Afatinib—Dermatitis—Epirubicin—bone cancer	9.4e-05	0.00144	CcSEcCtD
Afatinib—Headache—Epirubicin—bone cancer	9.35e-05	0.00144	CcSEcCtD
Afatinib—Dizziness—Doxorubicin—bone cancer	9.13e-05	0.0014	CcSEcCtD
Afatinib—Nausea—Epirubicin—bone cancer	8.86e-05	0.00136	CcSEcCtD
Afatinib—Vomiting—Doxorubicin—bone cancer	8.78e-05	0.00135	CcSEcCtD
Afatinib—Rash—Doxorubicin—bone cancer	8.7e-05	0.00134	CcSEcCtD
Afatinib—Dermatitis—Doxorubicin—bone cancer	8.7e-05	0.00134	CcSEcCtD
Afatinib—Headache—Doxorubicin—bone cancer	8.65e-05	0.00133	CcSEcCtD
Afatinib—Nausea—Doxorubicin—bone cancer	8.2e-05	0.00126	CcSEcCtD
Afatinib—PHKG2—Disease—PTGS2—bone cancer	4.62e-05	0.000352	CbGpPWpGaD
Afatinib—EPHA6—Developmental Biology—EGFR—bone cancer	4.62e-05	0.000352	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	4.61e-05	0.000351	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—ATF1—bone cancer	4.6e-05	0.00035	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—KIT—bone cancer	4.59e-05	0.000349	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—MET—bone cancer	4.58e-05	0.000348	CbGpPWpGaD
Afatinib—ABL1—Factors involved in megakaryocyte development and platelet production—TP53—bone cancer	4.56e-05	0.000347	CbGpPWpGaD
Afatinib—EGFR—Focal Adhesion—JUN—bone cancer	4.52e-05	0.000344	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.5e-05	0.000343	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—GRM1—bone cancer	4.48e-05	0.000341	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—BRAF—bone cancer	4.47e-05	0.000341	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—MMP2—bone cancer	4.47e-05	0.00034	CbGpPWpGaD
Afatinib—ERBB2—Disease—TGFBR2—bone cancer	4.42e-05	0.000337	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—MDM2—bone cancer	4.42e-05	0.000337	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—SMO—bone cancer	4.37e-05	0.000333	CbGpPWpGaD
Afatinib—EGFR—Spinal Cord Injury—TP53—bone cancer	4.37e-05	0.000333	CbGpPWpGaD
Afatinib—ERBB4—Disease—TGFBR2—bone cancer	4.36e-05	0.000332	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—MDM2—bone cancer	4.36e-05	0.000332	CbGpPWpGaD
Afatinib—LCK—Signaling by SCF-KIT—EGFR—bone cancer	4.35e-05	0.000331	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—BRAF—bone cancer	4.31e-05	0.000328	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—SMO—bone cancer	4.3e-05	0.000328	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—MDM2—bone cancer	4.25e-05	0.000323	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—MMP9—bone cancer	4.23e-05	0.000322	CbGpPWpGaD
Afatinib—ABL1—Integrated Breast Cancer Pathway—TP53—bone cancer	4.2e-05	0.000319	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—MDM2—bone cancer	4.18e-05	0.000319	CbGpPWpGaD
Afatinib—LCK—Downstream signaling of activated FGFR—EGFR—bone cancer	4.16e-05	0.000317	CbGpPWpGaD
Afatinib—IRAK1—Immune System—ATF1—bone cancer	4.15e-05	0.000316	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.14e-05	0.000315	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB4—EGFR—bone cancer	4.09e-05	0.000312	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.09e-05	0.000312	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—KIT—bone cancer	4.06e-05	0.000309	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL3—bone cancer	4.05e-05	0.000309	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—MDM2—bone cancer	4.02e-05	0.000306	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—GNA11—bone cancer	4e-05	0.000304	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—PLAU—bone cancer	3.97e-05	0.000302	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—GNA11—bone cancer	3.94e-05	0.0003	CbGpPWpGaD
Afatinib—LCK—Downstream signal transduction—EGFR—bone cancer	3.91e-05	0.000298	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR—EGFR—bone cancer	3.89e-05	0.000296	CbGpPWpGaD
Afatinib—PHKG2—Metabolism—PTGS2—bone cancer	3.87e-05	0.000295	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB2—EGFR—bone cancer	3.87e-05	0.000295	CbGpPWpGaD
Afatinib—LCK—DAP12 signaling—EGFR—bone cancer	3.85e-05	0.000293	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—JUN—bone cancer	3.84e-05	0.000293	CbGpPWpGaD
Afatinib—IRAK1—Signaling by NGF—EGFR—bone cancer	3.83e-05	0.000292	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—MET—bone cancer	3.82e-05	0.000291	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—CDK4—bone cancer	3.82e-05	0.000291	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—MMP2—bone cancer	3.82e-05	0.000291	CbGpPWpGaD
Afatinib—EGFR—Direct p53 effectors—TP53—bone cancer	3.81e-05	0.00029	CbGpPWpGaD
Afatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bone cancer	3.8e-05	0.000289	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—JUN—bone cancer	3.79e-05	0.000288	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—MDM2—bone cancer	3.75e-05	0.000285	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—ATF1—bone cancer	3.72e-05	0.000283	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NDUFA12—bone cancer	3.71e-05	0.000282	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—ATF1—bone cancer	3.66e-05	0.000279	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—EGFR—bone cancer	3.62e-05	0.000276	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—EGFR—bone cancer	3.62e-05	0.000276	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	3.62e-05	0.000276	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL3—bone cancer	3.62e-05	0.000276	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—MDM2—bone cancer	3.61e-05	0.000275	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—EGFR—bone cancer	3.59e-05	0.000273	CbGpPWpGaD
Afatinib—EGFR—Integrated Breast Cancer Pathway—TP53—bone cancer	3.58e-05	0.000273	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—SMO—bone cancer	3.58e-05	0.000272	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL3—bone cancer	3.57e-05	0.000272	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—EGFR—bone cancer	3.56e-05	0.000271	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—EGFR—bone cancer	3.54e-05	0.00027	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.52e-05	0.000268	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.48e-05	0.000265	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RGS1—bone cancer	3.46e-05	0.000263	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—GRM4—bone cancer	3.46e-05	0.000263	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—EGFR—bone cancer	3.42e-05	0.000261	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—MMP9—bone cancer	3.36e-05	0.000256	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—EGFR—bone cancer	3.35e-05	0.000255	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RGS1—bone cancer	3.33e-05	0.000254	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—GRM4—bone cancer	3.33e-05	0.000254	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—TP53—bone cancer	3.29e-05	0.000251	CbGpPWpGaD
Afatinib—PHKG2—Disease—EGFR—bone cancer	3.28e-05	0.00025	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—GNA11—bone cancer	3.27e-05	0.000249	CbGpPWpGaD
Afatinib—ERBB2—Immune System—KIT—bone cancer	3.27e-05	0.000249	CbGpPWpGaD
Afatinib—LCK—Hemostasis—PLAU—bone cancer	3.27e-05	0.000249	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—CDK4—bone cancer	3.27e-05	0.000249	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—MET—bone cancer	3.27e-05	0.000249	CbGpPWpGaD
Afatinib—ABL1—Immune System—ATF1—bone cancer	3.25e-05	0.000248	CbGpPWpGaD
Afatinib—ERBB4—Immune System—KIT—bone cancer	3.22e-05	0.000245	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	3.21e-05	0.000244	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—MDM2—bone cancer	3.2e-05	0.000243	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—MMP2—bone cancer	3.19e-05	0.000243	CbGpPWpGaD
Afatinib—EGFR—Disease—ENO2—bone cancer	3.18e-05	0.000242	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—KIT—bone cancer	3.18e-05	0.000242	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL3—bone cancer	3.17e-05	0.000241	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SMO—bone cancer	3.16e-05	0.000241	CbGpPWpGaD
Afatinib—BLK—Immune System—KIT—bone cancer	3.1e-05	0.000236	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TGFBR2—bone cancer	3.1e-05	0.000236	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NT5C3A—bone cancer	3.07e-05	0.000234	CbGpPWpGaD
Afatinib—LCK—Disease—ENO2—bone cancer	3.07e-05	0.000234	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TGFBR2—bone cancer	3.05e-05	0.000232	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—EGFR—bone cancer	3.02e-05	0.00023	CbGpPWpGaD
Afatinib—ERBB2—Disease—KIT—bone cancer	3.02e-05	0.00023	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—GRM1—bone cancer	3e-05	0.000228	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—EGFR—bone cancer	2.98e-05	0.000227	CbGpPWpGaD
Afatinib—ERBB4—Disease—KIT—bone cancer	2.97e-05	0.000227	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.97e-05	0.000226	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL3—bone cancer	2.96e-05	0.000226	CbGpPWpGaD
Afatinib—EGFR—Disease—DHFR—bone cancer	2.95e-05	0.000225	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IGF1R—bone cancer	2.92e-05	0.000222	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—EGFR—bone cancer	2.9e-05	0.000221	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—GNA11—bone cancer	2.89e-05	0.00022	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—GRM1—bone cancer	2.89e-05	0.00022	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IGF1R—bone cancer	2.87e-05	0.000219	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—MMP9—bone cancer	2.87e-05	0.000218	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—EGFR—bone cancer	2.86e-05	0.000218	CbGpPWpGaD
Afatinib—LCK—Disease—DHFR—bone cancer	2.84e-05	0.000217	CbGpPWpGaD
Afatinib—ERBB2—Disease—BRAF—bone cancer	2.84e-05	0.000216	CbGpPWpGaD
Afatinib—ERBB4—Disease—BRAF—bone cancer	2.8e-05	0.000213	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—JUN—bone cancer	2.78e-05	0.000212	CbGpPWpGaD
Afatinib—EGFR—Immune System—ATF1—bone cancer	2.78e-05	0.000212	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—EGFR—bone cancer	2.75e-05	0.000209	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—MMP2—bone cancer	2.72e-05	0.000207	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—KIT—bone cancer	2.71e-05	0.000207	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—EGFR—bone cancer	2.71e-05	0.000207	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL3—bone cancer	2.71e-05	0.000206	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ATF1—bone cancer	2.69e-05	0.000205	CbGpPWpGaD
Afatinib—LCK—Immune System—ATF1—bone cancer	2.68e-05	0.000204	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL3—bone cancer	2.62e-05	0.000199	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—KIT—bone cancer	2.62e-05	0.000199	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.61e-05	0.000199	CbGpPWpGaD
Afatinib—LCK—Immune System—IL3—bone cancer	2.61e-05	0.000199	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—KIT—bone cancer	2.61e-05	0.000199	CbGpPWpGaD
Afatinib—ERBB2—Immune System—MDM2—bone cancer	2.58e-05	0.000196	CbGpPWpGaD
Afatinib—ERBB4—Immune System—MDM2—bone cancer	2.54e-05	0.000193	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.52e-05	0.000192	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—KIT—bone cancer	2.51e-05	0.000191	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—MDM2—bone cancer	2.5e-05	0.000191	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ENO2—bone cancer	2.49e-05	0.000189	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—EGFR—bone cancer	2.47e-05	0.000188	CbGpPWpGaD
Afatinib—BLK—Immune System—MDM2—bone cancer	2.44e-05	0.000186	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—MMP9—bone cancer	2.4e-05	0.000182	CbGpPWpGaD
Afatinib—ERBB2—Disease—MDM2—bone cancer	2.38e-05	0.000181	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KIT—bone cancer	2.36e-05	0.00018	CbGpPWpGaD
Afatinib—ERBB4—Disease—MDM2—bone cancer	2.34e-05	0.000178	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—DHFR—bone cancer	2.31e-05	0.000176	CbGpPWpGaD
Afatinib—ERBB2—Disease—PTGS2—bone cancer	2.29e-05	0.000175	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.27e-05	0.000173	CbGpPWpGaD
Afatinib—ERBB4—Disease—PTGS2—bone cancer	2.26e-05	0.000172	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TGFBR2—bone cancer	2.24e-05	0.000171	CbGpPWpGaD
Afatinib—ERBB2—Immune System—JUN—bone cancer	2.24e-05	0.00017	CbGpPWpGaD
Afatinib—ERBB4—Immune System—JUN—bone cancer	2.21e-05	0.000168	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—EGFR—bone cancer	2.18e-05	0.000166	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—JUN—bone cancer	2.17e-05	0.000166	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GNA11—bone cancer	2.16e-05	0.000164	CbGpPWpGaD
Afatinib—EGFR—Disease—TGFBR2—bone cancer	2.14e-05	0.000163	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—MDM2—bone cancer	2.14e-05	0.000163	CbGpPWpGaD
Afatinib—BLK—Immune System—JUN—bone cancer	2.12e-05	0.000162	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KIT—bone cancer	2.11e-05	0.000161	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SMO—bone cancer	2.11e-05	0.000161	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IGF1R—bone cancer	2.11e-05	0.000161	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KIT—bone cancer	2.08e-05	0.000159	CbGpPWpGaD
Afatinib—LCK—Disease—TGFBR2—bone cancer	2.06e-05	0.000157	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—MDM2—bone cancer	2.06e-05	0.000157	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—MDM2—bone cancer	2.05e-05	0.000156	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—MMP9—bone cancer	2.05e-05	0.000156	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SMO—bone cancer	2.04e-05	0.000155	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—BRAF—bone cancer	1.99e-05	0.000151	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—MDM2—bone cancer	1.98e-05	0.000151	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—BRAF—bone cancer	1.96e-05	0.000149	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CYP3A4—bone cancer	1.96e-05	0.000149	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—EGFR—bone cancer	1.94e-05	0.000147	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—GNA11—bone cancer	1.93e-05	0.000147	CbGpPWpGaD
Afatinib—IRAK1—Immune System—MDM2—bone cancer	1.86e-05	0.000142	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—GNA11—bone cancer	1.86e-05	0.000142	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—JUN—bone cancer	1.86e-05	0.000142	CbGpPWpGaD
Afatinib—ABL1—Immune System—KIT—bone cancer	1.85e-05	0.000141	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ATF1—bone cancer	1.8e-05	0.000137	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—JUN—bone cancer	1.79e-05	0.000136	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.79e-05	0.000136	CbGpPWpGaD
Afatinib—ERBB2—Immune System—EGFR—bone cancer	1.76e-05	0.000134	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL3—bone cancer	1.75e-05	0.000133	CbGpPWpGaD
Afatinib—ERBB4—Immune System—EGFR—bone cancer	1.73e-05	0.000132	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ATF1—bone cancer	1.73e-05	0.000132	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—EGFR—bone cancer	1.71e-05	0.00013	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL3—bone cancer	1.69e-05	0.000129	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GSTP1—bone cancer	1.67e-05	0.000127	CbGpPWpGaD
Afatinib—BLK—Immune System—EGFR—bone cancer	1.67e-05	0.000127	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MDM2—bone cancer	1.67e-05	0.000127	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MDM2—bone cancer	1.64e-05	0.000125	CbGpPWpGaD
Afatinib—ERBB2—Disease—EGFR—bone cancer	1.63e-05	0.000124	CbGpPWpGaD
Afatinib—IRAK1—Immune System—JUN—bone cancer	1.62e-05	0.000123	CbGpPWpGaD
Afatinib—ERBB4—Disease—EGFR—bone cancer	1.6e-05	0.000122	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—bone cancer	1.59e-05	0.000121	CbGpPWpGaD
Afatinib—EGFR—Immune System—KIT—bone cancer	1.58e-05	0.00012	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KIT—bone cancer	1.53e-05	0.000116	CbGpPWpGaD
Afatinib—LCK—Immune System—KIT—bone cancer	1.52e-05	0.000116	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.5e-05	0.000114	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TGFBR2—bone cancer	1.5e-05	0.000114	CbGpPWpGaD
Afatinib—EGFR—Disease—KIT—bone cancer	1.46e-05	0.000111	CbGpPWpGaD
Afatinib—ABL1—Immune System—MDM2—bone cancer	1.46e-05	0.000111	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—JUN—bone cancer	1.45e-05	0.00011	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TGFBR2—bone cancer	1.44e-05	0.00011	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—BRAF—bone cancer	1.44e-05	0.000109	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—JUN—bone cancer	1.43e-05	0.000109	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IGF1R—bone cancer	1.41e-05	0.000107	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MMP9—bone cancer	1.41e-05	0.000107	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—EGFR—bone cancer	1.41e-05	0.000107	CbGpPWpGaD
Afatinib—LCK—Disease—KIT—bone cancer	1.41e-05	0.000107	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MMP9—bone cancer	1.39e-05	0.000106	CbGpPWpGaD
Afatinib—EGFR—Disease—BRAF—bone cancer	1.37e-05	0.000104	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF1R—bone cancer	1.36e-05	0.000103	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—EGFR—bone cancer	1.35e-05	0.000103	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ENO2—bone cancer	1.35e-05	0.000102	CbGpPWpGaD
Afatinib—LCK—Disease—BRAF—bone cancer	1.32e-05	0.000101	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—bone cancer	1.31e-05	0.0001	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EGFR—bone cancer	1.27e-05	9.69e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—JUN—bone cancer	1.27e-05	9.65e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—DHFR—bone cancer	1.25e-05	9.5e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MDM2—bone cancer	1.25e-05	9.48e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MDM2—bone cancer	1.2e-05	9.17e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MDM2—bone cancer	1.2e-05	9.14e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GNA11—bone cancer	1.17e-05	8.88e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MDM2—bone cancer	1.15e-05	8.76e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—bone cancer	1.14e-05	8.67e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—bone cancer	1.12e-05	8.54e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—bone cancer	1.11e-05	8.44e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MDM2—bone cancer	1.11e-05	8.44e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—JUN—bone cancer	1.08e-05	8.24e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—bone cancer	1.07e-05	8.13e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP3A4—bone cancer	1.06e-05	8.05e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—JUN—bone cancer	1.05e-05	7.97e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—JUN—bone cancer	1.04e-05	7.94e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KIT—bone cancer	1.02e-05	7.78e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—bone cancer	1.02e-05	7.75e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—bone cancer	9.96e-06	7.58e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KIT—bone cancer	9.85e-06	7.5e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—BRAF—bone cancer	9.61e-06	7.32e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—bone cancer	9.55e-06	7.28e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—bone cancer	9.41e-06	7.17e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—BRAF—bone cancer	9.26e-06	7.05e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTP1—bone cancer	9.04e-06	6.89e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—bone cancer	8.66e-06	6.6e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—bone cancer	8.23e-06	6.27e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—bone cancer	8.2e-06	6.24e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MDM2—bone cancer	8.05e-06	6.13e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MDM2—bone cancer	7.76e-06	5.91e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—bone cancer	7.57e-06	5.77e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—JUN—bone cancer	7e-06	5.33e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—bone cancer	6.91e-06	5.26e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—bone cancer	6.81e-06	5.18e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—JUN—bone cancer	6.74e-06	5.14e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—bone cancer	6.56e-06	5e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—bone cancer	5.3e-06	4.04e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—bone cancer	4.68e-06	3.57e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—bone cancer	4.62e-06	3.52e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—bone cancer	4.45e-06	3.39e-05	CbGpPWpGaD
